Navigation Links
Avanir Pharmaceuticals Announces Publication Of PBA Burden Of Illness Study
Date:9/5/2012

from PBA describe their episodes as uncontrollable, exaggerated, or different from their true feelings. PBA may occur when certain neurologic diseases or injury damage the areas of the brain that control normal expression of emotion. This damage can disrupt brain signaling, causing a "short circuit" and triggering episodes of involuntary crying or laughing. PBA can occur in people diagnosed with a variety of otherwise unrelated neurologic conditions such as Lou Gehrig's disease (ALS), multiple sclerosis (MS), Parkinson's disease, stroke, traumatic brain injury (TBI), and Alzheimer's disease. For more information about PBA, please visit www.PBAinfo.org.

About Harris Interactive
Harris Interactive is one of the world's leading custom market research firms, leveraging research, technology, and business acumen to transform relevant insight into actionable foresight. Known widely for The Harris Poll and for pioneering innovative research methodologies, Harris offers expertise in a wide range of industries including healthcare, technology, public affairs, energy, telecommunications, financial services, insurance, media, retail, restaurant, and consumer package goods. Serving clients in over 215 countries and territories through our North American, European, and Asian offices and a network of independent market research firms, Harris specializes in delivering research solutions that help us - and our clients - stay ahead of what's next. For more information, please visit www.harrisinteractive.com.

About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of pati
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimers Disease
2. Avanir Pharmaceuticals To Present At Two Investor Conferences In August
3. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Third Quarter Financial Results And Conference Call
4. Avanir Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
5. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call
6. Avanir Pharmaceuticals To Present at Three Conferences In May
7. Savient Pharmaceuticals to Present at the 6th Annual Imperial Capital Global Opportunities Conference
8. Questcor Pharmaceuticals to Present at Investor Conferences in September
9. Intercept Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
10. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
11. Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
(Date:4/23/2014)... Oncotarget , explored tumour heterogeneity where ... DNA signatures within the same cancer. Such differences ... treatment strategies. , Firstly they confirmed the mutual ... KRAS or BRAF mutation. Secondly, they found that ... have that specific mutation present uniformly throughout the ...
(Date:4/23/2014)... of endogenous neural precursor cells cannot alone compensate ... the perspective of neural plasticity, Dr. Yun Xiang ... observed the effects of functional electrical stimulation treatment ... of basic fibroblast growth factor and epidermal growth ... side. The researchers found that functional electrical stimulation ...
(Date:4/22/2014)... the United States with 1 million participants annually. A ... Injury Research and Policy at Nationwide Children,s Hospital is ... distribution patterns of basketball-related injuries treated in emergency departments ... and teens. , The study, published online in the ... to adolescents 13-19 years of age who were treated ...
(Date:4/22/2014)... recently FDA-approved device has been shown to reduce seizures ... 50 percent. When coupled with an innovative electrode placement ... facilitated the complete elimination of seizures in nearly half ... clinical trials. , That,s good news for a large ... living with epilepsy whose seizures can,t be controlled with ...
(Date:4/22/2014)... that can provide primary care for low-income patients ... and insurance companies while improving patient health, researchers ... suggests that health clinics that avoid costs associated ... by lowering hospital admission rates and emergency room ... Penn State Altoona. , The researchers estimated ...
Breaking Medicine News(10 mins):Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2
... recommended treatments, study found , FRIDAY, May 28 (HealthDay ... designed to review current research and guidelines, doctors made ... patients with high blood pressure, a new study reports. ... reflected in the practices of community physicians remains a ...
... Chase Cancer Center investigators find that pancreatic cancer patients who ... patients without circulating tumor cells. Additionally, the team has uncovered ... and some may predict worse outcomes than others. Benjamin ... will present the study at the 46th Annual Meeting of ...
... the final details on how two stroke-prevention procedures are safe ... stroke, though their effectiveness does vary by age, say researchers ... Public Health in collaboration with other North American stroke investigators. ... Journal of Medicine (NEJM) May 26, the researchers say ...
... ... range of crystalens to benfit the patients. , ... (Vocus) -- Dr. Khanna and crystal lens have had a symbiotic relationship ... has especially been helpful in people who have undergone radial RK or macular degeneration. ...
... to be self-centered, competitive, U.S. research shows , FRIDAY, May ... reveals that American college students are not quite as empathetic ... drop in empathy after the year 2000," co-author Sara Konrath, ... Research, said in a news release. "College kids today are ...
... brain, still befuddles patients and researchers, , FRIDAY, May 28 ... be a lifeline to the future. And more aggressive, high-dose ... there,s a downside, too: Chemotherapy is linked to a mental ... dismissed as "all in your head," but that,s no longer ...
Cached Medicine News:Health News:Putting New Medical Guidelines Into Practice Often Difficult 2Health News:Circulating tumor cells correlate with poorer survival in pancreatic cancer patients 2Health News:Age is a factor in choosing between two comparable stroke-prevention procedures 2Health News:Khannna Institute to offer Crystalens in Quarter Diopter Steps 2Health News:Today's College Students More Likely to Lack Empathy 2Health News:Making Your Way Through the Fog of Chemotherapy 2Health News:Making Your Way Through the Fog of Chemotherapy 3
Cushing periosteal elevators, rounded edge, sharp, wide, blade width 5/8" (16 mm), length 7 1/4" (184 mm)....
Barr periosteal elevators....
Molt 9 periosteal elevators....
Miller Collburn periosteal elevators....
Medicine Products: